Departments of Medicine and Oral and Maxillofacial Surgery, Division of Neuroscience, and UCSF Pain and Addiction Research Center, University of California at San Francisco, San Francisco, California 94143.
Departments of Medicine and Oral and Maxillofacial Surgery, Division of Neuroscience, and UCSF Pain and Addiction Research Center, University of California at San Francisco, San Francisco, California 94143
J Neurosci. 2021 Jan 6;41(1):31-46. doi: 10.1523/JNEUROSCI.2160-20.2020. Epub 2020 Nov 17.
Clinical µ-opioid receptor (MOR) agonists produce hyperalgesic priming, a form of maladaptive nociceptor neuroplasticity, resulting in pain chronification. We have established an model of opioid-induced hyperalgesic priming (OIHP), in male rats, to identify nociceptor populations involved and its maintenance mechanisms. OIHP was induced by systemic administration of fentanyl and confirmed by prolongation of prostaglandin E (PGE) hyperalgesia. Intrathecal cordycepin, which reverses Type I priming, or the combination of Src and mitogen-activated protein kinase (MAPK) inhibitors, which reverses Type II priming, both partially attenuated OIHP. Parallel experiments were performed on small-diameter (<30 µm) dorsal root ganglion (DRG) neurons, cultured from fentanyl-primed rats, and rats with OIHP treated with agents that reverse Type I or Type II priming. Enhancement of the sensitizing effect of a low concentration of PGE (10 nm), another characteristic feature of priming, measured as reduction in action potential (AP) rheobase, was found in weakly isolectin B4 (IB4)-positive and IB4-negative (IB4-) neurons. In strongly IB4-positive (IB4+) neurons, only the response to a higher concentration of PGE (100 nm) was enhanced. The sensitizing effect of 10 nm PGE was attenuated in weakly IB4+ and IB4- neurons cultured from rats whose OIHP was reversed Thus, administration of fentanyl induces neuroplasticity in weakly IB4+ and IB4- nociceptors that persists and has properties of Type I and Type II priming. The mechanism underlying the enhanced sensitizing effect of 100 nm PGE in strongly IB4+ nociceptors, not attenuated by inhibitors of Type I and Type II priming, remains to be elucidated. Commonly used clinical opioid analgesics, such as fentanyl and morphine, can produce hyperalgesia and chronification of pain. To uncover the nociceptor population mediating opioid-induced hyperalgesic priming (OIHP), a model of pain chronification, and elucidate its underlying mechanism, at the cellular level, we established an model of OIHP. In dorsal root ganglion (DRG) neurons cultured from rats primed with fentanyl, robust nociceptor population-specific changes in sensitization by prostaglandin E (PGE) were observed, when compared with nociceptors from opioid naive rats. In DRG neurons cultured from rats with OIHP, enhanced PGE-induced sensitization was observed , with differences identified in non-peptidergic [strongly isolectin B4 (IB4)-positive] and peptidergic [weakly IB4-positive (IB4+) and IB4-negative (IB4-)] nociceptors.
临床µ-阿片受体(MOR)激动剂产生痛觉过敏引发,这是一种适应性伤害感受器神经可塑性的形式,导致疼痛慢性化。我们已经建立了一种 阿片类药物引起的痛觉过敏引发(OIHP)的模型,在雄性大鼠中,以确定涉及的伤害感受器群体及其维持机制。通过全身给予芬太尼诱导 OIHP,并通过延长前列腺素 E(PGE)痛觉过敏来证实。鞘内给予虫草素,可逆转 I 型引发,或 Src 和丝裂原活化蛋白激酶(MAPK)抑制剂的组合,可逆转 II 型引发,均可部分减轻 OIHP。在从小鼠(已用芬太尼引发)和接受可逆转 I 型或 II 型引发的药物治疗的 OIHP 大鼠中分离的小直径(<30 µm)背根神经节(DRG)神经元上进行了平行实验。测量动作电位(AP)阈电流的降低,发现对低浓度 PGE(10nm)的敏化作用增强,这是引发的另一个特征,在弱异凝集素 B4(IB4)阳性和 IB4-(IB4-)神经元中发现。在强 IB4+(IB4+)神经元中,仅对更高浓度的 PGE(100nm)的反应增强。在 OIHP 被逆转的大鼠中培养的弱 IB4+和 IB4-神经元中,10nm PGE 的敏化作用减弱。因此,芬太尼的给药会导致弱 IB4+和 IB4-伤害感受器发生可塑性变化,这种变化持续存在,具有 I 型和 II 型引发的特性。在强 IB4+伤害感受器中,100nm PGE 的敏化作用增强,而 I 型和 II 型引发抑制剂不能减弱,其潜在机制仍有待阐明。常用的临床阿片类镇痛药,如芬太尼和吗啡,可引起痛觉过敏和疼痛的慢性化。为了揭示介导阿片类药物引起的痛觉过敏引发(OIHP)的伤害感受器群体,建立了一种疼痛慢性化的模型,并在细胞水平上阐明其潜在机制,我们建立了一种 OIHP 模型。在从小鼠中培养的芬太尼引发的 DRG 神经元中,与阿片类药物未处理的大鼠相比,观察到 PGE 引起的敏化作用有明显的伤害感受器群体特异性变化。在 OIHP 大鼠的 DRG 神经元中,观察到增强的 PGE 诱导的敏化作用,在非肽能[强 IB4+(IB4+)]和肽能[弱 IB4+(IB4+)和 IB4-]伤害感受器中发现了差异。